ASCO - TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial - Session Highlights

CHICAGO, IL USA ( - Dr. Gillian Duchesne, a radiation oncologist from the Peter MacCallum Cancer Center in Melbourne, Australia, presented the initial results of the TOAD study, a phase III randomized clinical trial assessing the timing of androgen deprivation therapy (ADT) among asymptomatic men with biochemical recurrence of prostate cancer.

ASCO - A phase III protocol of androgen suppression and radiotherapy vs. AS and RT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer - Session Highlights

CHICAGO, IL USA ( - Dr. Howard Sandler of Cedars-Sinai presented the results of RTOG 0521. The study sought to improve outcomes associated with treatment of locally advanced or high-risk localized prostate cancers that traditionally have a high risk of recurrence despite the use of standard of care radiotherapy and 2-3 years of concurrent androgen deprivation therapy (ADT).

ASCO - First-ever evidence shows adjuvant chemotherapy improves overall survival in high-risk, localized prostate cancer - Session Highlights

CHICAGO, IL USA ( - Adding docetaxel to standard hormone and radiation therapy reduced the risk of death for men with high-risk, localized prostate cancer in results reported at the 2015 ASCO Annual Meeting, in Chicago, IL.  At a median follow-up of 5.5 years in this phase III study RTOG 0521, overall survival (OS) rates were 93% in the docetaxel-treated group vs. 89% in the standard therapy group.

ASCO - Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE - Session Highlights

CHICAGO, IL USA ( - Dr. Nicholas James presented the initial survival results from the STAMPEDE study of men with metastatic or biochemical recurrent hormone sensitive prostate cancer.

ASCO - Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration resistant prostate cancer - Session Highlights

CHICAGO, IL USA ( - Dr. Howard Scher of Memorial Sloan Kettering presented the Prostate Cancer Working Group 3 (PCWG3) Consensus Guidelines, an update from the previously published Prostate Cancer Working Group 2 (PCWG2) set published in 2008.

ASCO - ARAMIS: Novel oral androgen receptor inhibitor ODM-201 enters phase 3 study in nmCRPC - Session Highlights

CHICAGO, IL USA ( - Along with evidence of the long-term efficacy and safely of a novel oral androgen receptor -- ODM-201[1] – details of the launch of a phase 3 study, now open and recruiting, were presented at the 2015 ASCO Annual Meeting, in Chicago, IL.

#ASCO15 - ODM-201 demonstrates high anticancer activity and favorable tolerability in the ARADES phase I/II trial in mCRPC - Session Highlights

CHICAGO, IL USA ( - The novel, oral, high-affinity inhibitor of the androgen receptor, ODM-201, was shown to possess high anticancer activity and a favorable tolerability profile in long-term results from the international phase I/II ARADES study, with data at 38 weeks that were consistent with earlier-reported 12-week efficacy and safety among progressive mCRPC patients.[1]

Page 1 of 2

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.